Shimadzu has released the CLAM-2030 fully automated preparation module for LCMS. This module automates everything from the preparation of urine, blood, and other biological samples to measurement via liquid chromatography mass spectrometry (LCMS). Conventionally, when measuring blood samples with LCMS, it takes 15 to 20 minutes for the preparatory process, which includes the addition of reagents, mixing of the solution, and the addition of a deproteinization liquid. The CLAM-2030 preparation module, in contrast, completes this process in 3 to 8 minutes. Further, if the samples and reagents are placed and positioned in special containers for automatic conveyance to the LCMS by an autosampler, the module can perform all of the processes automatically, on holidays and overnight.
In recent years, at clinical research sites, the monitoring of drug concentrations in blood samples, searches for biomarkers, and metabolic evaluations have become prevalent due to the arrival of LCMS, which is capable of high-sensitivity analysis and high-speed processing. At the same time, because preparation is indispensable for blood sample analysis, and the processing of infectious samples including pathogens is required, issues remain with respect to the time and workload involved in the measurement of large quantities of samples. In 2015, Shimadzu released the SCLAM-2000 fully automated preparation module for LCMS, a precursor to the CLAM-2030, as a means of improving the efficiency of the analysis process. In 2017, this instrument was registered as a class 1 medical device.
In response to the needs at clinical research sites, the CLAM-2030 provides stable data acquisition, lower running costs, and improved work efficiency. The module can be connected to four models of triple quadrupole liquid chromatograph mass spectrometers, the LCMS-8040, LCMS-8045, LCMS-8050, and LCMS-8060. Work efficiency is further improved by using it in combination with a commercial analysis kit.
Shimadzu is involved in the advanced healthcare business, creating revolutionary products and services in the medical field as part of our current medium-term management plan. We will continue to research and develop products and technologies, doing our best for medical personnel and their patients through the widespread adoption of Shimadzu products at clinical sites.